News
Monoclonal antibodies may prevent CTE
Kun Ping Lu, MD, PhD and his research team at Beth Israel Deaconess Medical Center and Harvard Medical school have connected the development of CTE with high levels of cis P-tau, a protein associated with the plaques seen in CTE (Chronic Traumatic Encephalopathy). The build-up is seen as early as 12 hours to 2 months after the injury and spreading from the cortex to the hypothalmus over time. The research team found that a monoclonal anti-body was effective to reducing cis P-tau levels in the mouse study they conducted. If the monoclonal antibody therapy can prevent cis P-tau in humans it may go a long way to dealing with neurodegenerative problems associated with brain injury like CTE and Alzheimers Disease.
Click here to read the MedPage story about this research.
